 CohBar, Inc. CWBR, a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced its poster abstract for the American Thoracic Society ATS 2020 International Conference was published in todays edition of the American Journal of Respiratory and Critical Care Medicine. CohBars poster will contain data on a family of novel analogs of a peptide encoded in mitochondrial DNA, demonstrating beneficial effects in mouse models of Idiopathic Pulmonary Fibrosis IPF. 